NL-OMON34559已完成3 期
An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - Ferring_CS35A
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Ferring
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who complete the main trial (CS35) after the initiation of CS35A will be eligible for inclusion in the CS35A extension trial. Signed informed consent will be obtained before any trial-related activity is performed.
排除标准
- •Patients who complete the main trial (CS35) after the initiation of CS35A will be eligible for inclusion in the CS35A extension trial. Signed informed consent will be obtained before any trial-related activity is performed.
研究者
相似试验
进行中（未招募）
不适用
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - CS35AMedDRA version: 13.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2010-021434-55-GBFerring Pharmaceuticals A/S450
进行中（未招募）
不适用
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - CS35AMedDRA version: 12.1Level: LLTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2010-021434-55-DEFerring Pharmaceuticals A/S450
进行中（未招募）
1 期
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - CS35AProstate cancerEUCTR2010-021434-55-CZFerring Pharmaceuticals A/S450
进行中（未招募）
1 期
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - CS35AMedDRA version: 13.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2010-021434-55-BEFerring Pharmaceuticals A/S450
进行中（未招募）
不适用
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - CS35AMedDRA version: 12.1Level: LLTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2010-021434-55-NLFerring Pharmaceuticals A/S450